drugset / Trial / NCT04110535
Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users
RandomizedCrossoverQuadruple-blindTreatment
Summary
A double-blind, randomized crossover study to assess the subjective abuse potential of intravenous remimazolam compared to midazolam and placebo in recreational CNS depressant users
Timeline
- Start
- 2015-06-23
- Primary completion
- 2015-10-06
- Completion
- 2015-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Midazolam | Small molecule | 2.5 mg | Intravenous |
| Comparator | Midazolam | Small molecule | 5 mg | Intravenous |
| Subject | Remimazolam | Small molecule | 5 mg | Intravenous |
| Subject | Remimazolam | Small molecule | 10 mg | Intravenous |